Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radioligand AZD2995 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | Alzheimer's Disease (AD) patients |
| 2 | OTHER | Healthy volunteers |
| Name | Type | Description |
|---|---|---|
| Radioligand (11C)AZD2995 | DRUG | Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers. |
| Radioligand (11C)AZD2184 | DRUG | Single dose of i.v solution. Once for AD patients respective healthy volunteers. |
Inclusion Criteria: * Alzheimer´s Disease patients - 50-85 years- mild to moderate AD, clinical progression of AD over 12 months. * Healthy male volunteers: - Age 20-50 years, Body Mass Index: 18-30 kg/m2. * Clinically normal physical findings including normal blood pressure and pulse rate. Exclus...
Top 20 of 24 competitors
Radioligand AZD2995 is an investigational small molecule being studied for use in Alzheimer's disease. It is a positron emission tomography (PET) radioligand candidate intended for imaging beta amyloid in the brain. The drug is in Phase 1 clinical development and is not yet approved.
Radioligand AZD2995 targets beta amyloid, a protein that forms plaques in the brains of people with Alzheimer's disease. As a PET radioligand, it is designed to bind to beta amyloid so that it can be visualized using positron emission tomography imaging.
Radioligand AZD2995 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for Alzheimer's disease.
Radioligand AZD2995 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, with a total of 13 participants enrolled.
Radioligand AZD2995 has been studied in one clinical trial, identified as NCT00692705. This was a Phase 1 positron emission tomography (PET) study conducted in Sweden, evaluating [11C]AZD2995 and [11C]AZD2184 as candidate PET ligands for beta amyloid. The trial has been completed.
Radioligand AZD2995 is not the same as AZD2184. Both are separate candidate PET ligands for beta amyloid that were evaluated together in the same clinical trial, NCT00692705. The study compared the two compounds as potential imaging agents for Alzheimer's disease.